Prime Medicine $175 million IPO
The shares are listed on the Nasdaq Global Market
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
European Biotech Acquisition $200 million combination with Oculis
We are advising European Biotech Acquisition Corp. on its deSPAC transaction
Novo Nordisk $1.1 billion acquisition of Forma Therapeutics
We are advising Novo Nordisk on the transaction
Freeman Spogli investment in EverVet
We advised Tailwind Capital and EverVet on the transaction
Gilead Sciences $405 million acquisition of MiroBio
We are advising Gilead Sciences on the transaction
TPG Capital $1.1 billion take-private acquisition of Convey Health Solutions
We are advising TPG Capital on the transaction
Astorg acquisition of OPEN Health
We are advising Astorg on the transaction
GSK $3.3 billion acquisition of Affinivax
We are advising GSK on the acquisition
Bausch + Lomb $630 million IPO
We are advising Bausch Health on the separation of its eye health business into a new public company, Bausch + Lomb
HilleVax $200 million IPO
The shares are listed on the Nasdaq Global Select Market